Arno Therapeutics enrolls first patient in a Phase I/II trial evaluating onapristone in men with advanced castration-resistant prostate cancer
Arno Therapeutics, Inc., a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, has announced that it has enrolled the first patient in a Phase I/II trial...
New test could accurately predict prostate cancer recurrence
Researchers have created a test that they say can predict whether a man is at high risk of prostate cancer recurrence.The research team, led by Prof. Robert Bristow of the Princess Margaret Cancer Centre and the University of Toronto, both in Canada, presented their findings at the 33rd conference of the European Society for Radiotherapy and Oncology (ESTRO33) in Vienna, Italy.
Predicting prostate cancer survival by measuring circulating tumor cells
New research by USC Norris Comprehensive Cancer Center scientists demonstrates that measuring circulating tumor cells (CTCs) - the cells that spread cancer through the body - may be a better predictor of patient survival than the prostate specific antigen (PSA).The research was published in the Journal of Clinical Oncology by a team led by Amir Goldkorn, M.D.
New Prostate Cancer drugs may not target root cause of the disease, York scientists warn
New drugs being developed for the treatment of prostate cancer may not be targeting the root cause of the disease, according to research published in Cell Death & Differentiation.Scientists at the University of York have discovered that a process called 'methylation', previously thought to drive the development of cancer, occurs in cells that are already cancerous.
Experts cite new drug therapies as rationale for improvements in prostate cancer guidelines, coordination
With a deluge of promising new drug treatments for advanced prostate cancer on the market, a new model of care is needed that emphasizes collaboration between urologists and medical oncologists, according to UC Davis prostate cancer experts.In an article published online in the journal Urologic Oncology, urologist Ralph de Vere White and medical oncologist Primo Lara, Jr.
|More Prostate Cancer News|